Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
Menu
NET Nurse
Donate
What are NETs?
Patients & Carers
Healthcare Professionals
Get Involved
NET Nurse
Donate
What are NETs?
  • What are Neuroendocrine Cancers?
  • What are Pheos & Paras?
  • NET Symptoms
  • Causes
  • Treatments
  • Grades
National Action Plan
Patients & Carers
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • Patient Stories
  • Share your Story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
National Action Plan
Healthcare Professionals
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
National Action Plan
Get Involved
  • Advocate for Us
  • Share your Story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
National-Action-Plan-1.png
NET Nurse
Donate

Home » Research » Sydney Cardiologists Perform World First

Sydney Cardiologists Perform World First

  • March 22, 2015

Carcinoid heart disease occurs in up to 20% of patients with symptoms of carcinoid syndrome (diarrhoea, flushing, abdominal pain, bronchospasm (asthma).
Excess serotonin, a hormone released by the NET tumours into the bloodstream affects the heart by causing thick ‘plaques’ within the heart muscle and damage to  valves (tricuspid and pulmonary) on the right side of the which become ‘tightly narrowed’ or ‘leaky’. Patients with carcinoid heart disease present with symptoms such as breathlessness, fatigue, enlarged liver and swollen ankles and without treatment can develop right heart failure.
Somatostatin analogues (octreotide, lanreotide etc) can slow the progression of carcinoid heart disease, however, some patients may need cardiac surgery to replace the narrowed or leaking valves to improve their symptoms and quality of life.  Cardiac surgery for valve replacement necessitates that the patient have open heart surgery and be put on ‘cardiopulmonary’ bypass machine while the cardiac surgeon replaces the valve. Some patients are too unwell or unwilling to undergo such significant surgery.

           

In a world first, two prominent Sydney interventional Cardiologists – Dr David Tanous and Dr Philip Roberts have percutaneously implanted an artificial valve into a NET patient, treating her narrowed pulmonary valve. In this procedure, a catheter was inserted into the femoral vein (in the groin) and with the assistance of x-ray imaging, an artificial valve was placed across the narrowed valve. Sheryl, who had been suffering from carcinoid heart disease for some time, now ‘feels well enough to return to work”.

   

On the day I saw her she proclaimed that she felt wonderful and had more energy and was surprised that her recovery time was so quick. The Unicorn Foundation is excited about the use of this treatment and its future potential in NET patients with symptomatic and significant carcinoid heart disease. Dr John Leyden

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Online survey for NET patients

September 26, 2023

Medicines Australia PharmAus event in Canberra

September 26, 2023

INCA Annual Summit 2023

September 26, 2023

Have your say on #EndGenderBias in Australia’s healthcare system

September 19, 2023
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousThank You Tour De Cure
NextNET Nurse Service – Patient SurveyNext

Related Posts

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Read full report

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness
  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness

Patients & Carers

  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS

Healthcare Professionals

  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources

Get Involved

  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2023 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin

What's on?

How to identify a neuroendocrine cancer when it’s not part of the typical line up. A RACGP & ACN CPD accredited course.

Share this course with your healthcare professional so they can enrol in this free online course and learn more about how to diagnose and treat NETs in general practice.

Learn More